Clinical Trials · NCT02533453
A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 110
- Start date
- Jan 2016
- Locations
- 15 sites, South Korea
- Primary endpoint
- Percentage of Participants With Adverse Events(AEs) and Serious Adverse Event(SAEs)